medigraphic.com
ISSN 1995-9427 (Print)

2020, Number 1

<< Back Next >>

Invest Medicoquir 2020; 12 (1)

mieloma múltiple|trasplante autólogo de células progenitoras hematopoyéticas|

Figueredo PYE, Capote CT, Luna CCM, Gutiérrez GCG, Wilford LMA, Campos ML

Language: Spanish
References: 19
Page:
PDF size: 445.36 Kb.


ABSTRACT

Introduction. Multiple myeloma is an incurable disease secondary to transformed clonal plasma cells. According to the World Health Organization, multiple myeloma represents 1% of malignant neoplasms and between 10-15 % of hematological malignancies, rarely affects subjects less than 30 years of age and in 90 % affects subjects older than 50 years. Methods. 79 patients were diagnosed with a diagnosis of multiple myeloma in the Hematology Department of the Surgical Medical Research Center. The data for the development of the research were obtained from medical records. Results. Male sex, the white skin color, age group over 60 years and the clinical form of active symptomatic excelled in patients studied. The most commonly used initial induction scheme was melphalan / prednisone / thalidomide / zometa and autologous hematopoietic progenitor transplantation. Conclusions. The general and relapse-free survival were higher than the mortality one year after diagnosis, with a gradual decrease during the entire period studied.


REFERENCES

  1. Kyle RA. Multiple myeloma: how did it begin? Mayo Clin Proc1994;69;680-6833. Perrin TG. Contribución al estudio de los plasmocitomas. Un caso de firoplasmocitoma osteógeno. Gac Med Mex 1925; 56;409-415.

  2. McKenna RW, Kyle RA, Kuehl WM, Grogan TM, et al. WHO Classifiation of Tumors of Hematopoyetic and Lymphoid Tissues. 4th ed. Lyon; 2008;200-213.

  3. Lin P. Plasma cell myeloma. Hematol Clin N A 2009;23:709-727.

  4. Kyle RA, Rajkumar SV. Multiple myleoma. Blood 2008; 111; 2962- 2972.

  5. Bladé J, Dimopoulos M, Rosiñol L, Rajkumar SV, Kyle RA.Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome and follow-up recommendations J Clin Oncol 2010;28:690-697. Epub 2009. Dec 21.

  6. Kyle RA. Five decades of therapy for multiple myeloma: a paradigm for therapeutic. Leukemia 2005;19:910-912.

  7. Díaz-Maqueo JC. Historia del mieloma. Rev Biomed 2006;17:225-229.

  8. Schleicher EM. Plasma cell. 100 year anniversary; a brief chronology. Minnesotta Medicine; 1977;60:131-133.

  9. Anaya A, Ramón y Cajal Junquera S, Langa MA. Las células cianófias de Cajal. Rev Esp Patol 2002;35:233-237.

  10. Dispenzieri A, Lacy M, Greipp P. Multiple Myeloma. En: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader BE (eds). Wintrobe's Clinical Hematology, 11th Edition. Lippincot Williams and Wilkins, 2004; 2583-2636.

  11. Birmann BM, Giovannucci E, Rosner B, Anderson KC, Colditz GA. Body mass index, physical activity, and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 2007; 16(7):1474-1478.

  12. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111:2521-2526.

  13. Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined signifiance among white and black male United States veterans with prior autoimmune, infectious, inflmmatory, and allergic disorders. Blood 2008; 111(7):3388-3394.

  14. Ludwig FE. General treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol. 2016;11: 1427-1436.

  15. Mieloma múltiple en Chile. Características clínicas y sobrevida. 2007

  16. Kumar S, Rajkumar S, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008 Marzo;: p. 2516-20.

  17. Guía clínica de gammapatías monoclonales. Castilla-León. ; 2013.

  18. Shaji K, Dispenzieri A, Lacy M, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014 Mayo; 28: p. 1122-1128.

  19. Augustson BM, Begum G, Dunn J, Barth NJ, Davies F, Morgan G et al. Early Mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council Trials between 1980 and 2002 -Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005; 23: 9219-26.




2020     |     www.medigraphic.com